UNSPSC 51263175: Timolol maleate

This classification denotes a beta-adrenergic blocking agent with the molecular formula C13H24N4O3S.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P8Y54F701R, chemically known as 2-propanol, 1-(tert-butylamino)-3-((4-morpholino-1,2,5-thiadiazol-3-yl)oxy)-, (-)-, maleate (1:1) (salt) but more generally known as timolol maleate, which bears US NIH Compound Identifier 5281056. European Medicines Agency schedules Timolol maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04875MIG.

UNSPSC 51263175 Timolol maleate, a Commodity code, appears to show a mismatch between its nominal scope and the recent state and local solicitation activity captured in the available data. Timolol maleate is a pharmaceutical active ingredient used in ophthalmic and cardiovascular treatments, yet the single recent opportunity on record—Seminole County, Florida's IFB 60459723LAS—solicits Naloxone and Safe Drug Deactivation Systems, which fall outside the timolol maleate product line. The code does not reflect active procurement of timolol maleate or related pharmaceutical products by state and local health agencies, counties, or school districts in the recent opportunities block. Without a clearer pattern of state and local buying activity under this code, the code does not signal meaningful business development opportunity at this time.

The available data does not support characterization of the issuing-body mix, geographic spread, or representative recent opportunities for timolol maleate procurement. The single recorded opportunity (Seminole County, Florida, IFB, due July 26, 2023) is unrelated to the code's defined commodity. Firms pursuing pharmaceutical supply contracts with state and local health systems should verify whether timolol maleate and similar branded or generic pharmaceuticals are solicited under alternate UNSPSC codes, or contact individual procurement offices directly to establish buying patterns and forecast procurement pipelines for specific pharmaceutical products.